Advanced Accelerator Technologies AG
Advanced Accelerator Technologies AG (AAT) was founded in 2015 as a joint initiative between the Paul Scherrer Institute (PSI) and a range of industry partners, some of which are international. The main aim of AAT is to commercialize the PSI’s leading know-how concerning accelerators, experimentation, and large facilities, as well as the institute’s outstanding application expertise regarding particle beams and photons in the areas of science, research, and industrial processes.
Crystallise! AG is a young company that provides crystallographic services for identifying small molecule compounds and addresses the chemical, pharmaceutical and agro-industries.
Excelsus Structural Solutions (Swiss) AG
Excelsus is a spin-off company of the Paul Scherrer Institute (PSI). It offers a fast, easy and affordable access to state-of-the-art characterization tools for the structural and microstructural analysis of materials (pharmaceuticals, food and aroma compounds, pigments, polymers as well as various other chemicals), for the selection, development and manufacturing of high-quality products.
Cosylab Switzerland GmbH
Cosylab Switzerland GmbH provides systems integration and customized products and solutions, covering the full range of control systems and instrumentation. Cosylab Switzerland was involved in the development of large-scale distributed control systems for PSI’s SwissFEL and SLS facilities.
GratXray is a high-tech spin-off of the PSI and ETH Zurich developing producing and commercializing a grating interferometry-based breast computed tomography (GIBCT) system. Their technology allows for more precise breast cancer imaging. It will significantly reduce the number of false positives and improve patients’ comfort during the procedure.
InterAx Biotech AG
InterAx is uniquely positioned to assist GPCR drug candidate design and selection by integrating bioanalytical and computational pharmacology in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms. Our goal is to close the gap between laboratory experiments and in vivo studies by streamlining the critical processes of drug candidate design and selection, thereby significantly reducing the risks, costs and duration of drug discovery and development of new drugs.
leadXpro AG specializes in the development and optimization of pharmaceutical active substances. The company applies research from the Paul Scherrer Institute (PSI) in the field of membrane proteins, as well as world-leading technologies to investigate protein structures. Further, the new large research facility at the PSI, the SwissFEL (launched in 2016), offers excellent potential for this close collaboration.
nomoko AG has developed a new technology to produce cost-effective and compact extremely high-resolution cameras. It is aiming to develop an 1-gigapixel camera that is smaller than a conventional digital single-lens reflex camera. Thanks to their superlative resolution, the resulting images have an extremely high level of detail and information density, rendering them ideal for use in robotics or simulations.
novoMOF AG is a technology company in the field of advanced materials with focus on synthesis and production of metal-organic frameworks (MOF). MOFs are novel materials that offer competitive applications in various industrial sectors. For instance, charging times of batteries can be reduced to minutes, the lifetime of packaged food can be prolonged or gases such as carbon dioxide can be separated, purified or stored. The company partners with leaders from different industries who want to exploit MOFs early as an innovation opportunity.
Swiss Hydrogen SA
Swiss Hydrogen SA was founded in 2008 as a subsidiary of Belenos Clean Power Holding to develop and market electrolysis products and services. The company works on clean energy solutions based on hydrogen for a variety of applications allowing for zero-emission electricity production.
Swiss Terahertz GmbH
SwissTerahertz is a start-up based on some world-unique terahertz technologies developed at the SwissFEL. It specializes in the fabrication and R&D of terahertz systems including highly-efficient nonlinear organic crystals. The products of Swiss Terahertz can be integrated both in specialized research infrastructures and in commercial spectrometers for security inspection, pharma, and non-destructive testing.
Molecular Modelling Laboratory (MML)
Molecular Modelling Laboratory (MML) applies high-throughput quantum chemical modelling, Artificial Intelligence (AI) heuristics and state-of-the-art electron microscopy to the study and development of life science immunointerventions and drug design. Quantum Immunology, MML’s flagship initiative, addresses how quantum mechanics translate into receptor-antigen triggering and how this knowledge may be applied to the therapy of infectious diseases, immune disorders, neurological conditions and aging. MML also combines theoretical modelling and Electron Energy Loss Spectroscopy (EELS) to optimize drug design through the detection of new polymorphic crystal structures and the analysis of pharmaceutical Amorphous Solid Dispersion (ASD) dynamics.